3/19/2010

Federal Trade Commission Chairman Jon Leibowitz said he thinks a proposal to prohibit pay-for-delay deals between brand-name and generic-drug companies will pass this year even if the measure gets dropped from the health reform bill. Leibowitz said bipartisan support is building for the proposal, which would restrict patent settlements that prevent the early launch of generic medicines.

Related Summaries